Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Aug 15, 2026; 18(8): 118698
Published online Aug 15, 2026. doi: 10.4251/wjgo.118698
Published online Aug 15, 2026. doi: 10.4251/wjgo.118698
Interaction between calcium channel blockers and capecitabine in colorectal cancer patients with hypertension
Hua-Cheng Lou, Department of Pharmacy, Hangzhou Tianshui Wulin Srteet Community Health Service Centers, Hangzhou 310005, Zhejiang Province, China
Xiao-Hua Liu, Department of Cardiology, Hangzhou First People’s Hospital, Hangzhou 310003, Zhejiang Province, China
Ping Jin, Department of Public Health Management, Hangzhou Tianshui Wulin Srteet Community Health Service Centers, Hangzhou 310005, Zhejiang Province, China
Jian-Min Wang, Department of Health Care, Hangzhou Tianshui Wulin Srteet Community Health Service Centers, Hangzhou 310005, Zhejiang Province, China
Bin Liu, Department of Pharmacy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, Hubei Province, China
Author contributions: Lou HC, Liu XH, Jin P and Wang JM contributed to research design, data collection, data analysis, and paper writing; Liu B was responsible for research design, funding application, data analysis, reviewing and editing, communication coordination, ethical review, copyright and licensing, and follow-up; all of the authors read and approved the final version of the manuscript to be published.
AI contribution statement: We didn’t use AI to write this manuscript. The high AI score likely comes from using translation software (DeepL) to improve the English. That can accidentally make the text read like AI. All text is human-written.
Institutional review board statement: The research was reviewed and approved by Hubei Cancer Hospital, No. LLHBCH2025YN-104.
Informed consent statement: All participants provided informed consent.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Data sharing statement: No other data available.
Corresponding author: Bin Liu, Associate Chief Pharmacist, Department of Pharmacy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Road, Hongshan District, Wuhan 430079, Hubei Province, China. liubinyl2024@163.com
Received: March 6, 2026
Revised: May 13, 2026
Accepted: June 12, 2026
Published online: August 15, 2026
Processing time: 149 Days and 11.7 Hours
Revised: May 13, 2026
Accepted: June 12, 2026
Published online: August 15, 2026
Processing time: 149 Days and 11.7 Hours
Core Tip
Core Tip: The current research paper examines the effects of combining calcium channel blockers and capecitabine on the treatment of colorectal cancer patients with associated hypertension. The results show that the use of amlodipine is more effective than valsartan in reducing tumor marker levels (carcinoembryonic antigen and carbohydrate antigen 19-9) with a better blood pressure control effect when combined with capecitabine. Therefore, there appears to be an interaction between calcium channel blockers and chemotherapy drugs that can be used to develop personalized anti-hypertensive therapy among colorectal cancer patients.